HMGB1 and neoplasm: Enhancing RT‐induced immunogenic cell death (ICD) has represented a promising strategy to overcome these challenges.[13, 14] During the ICD process, tumor cells expose calreticulin (CRT) on their surfaces and release adenosine triphosphate (ATP) and high mobility group box 1 (HMGB1), thereby providing critical antigens and immune adjuvants necessary for effective tumor vaccination.